|AI Robots Name||P/L|
|AI Robots Name||P/L|
GSK saw its Momentum Indicator move above the 0 level on November 17, 2022. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 40 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 48%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 18, 2022. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 26, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 251 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for GSK moved out of overbought territory on November 03, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GSK broke above its upper Bollinger Band on November 22, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.223) is normal, around the industry mean (5.315). P/E Ratio (12.804) is within average values for comparable stocks, (33.270). Projected Growth (PEG Ratio) (1.076) is also within normal values, averaging (4.319). GSK's Dividend Yield (0.056) is considerably higher than the industry average of (0.026). P/S Ratio (1.485) is also within normal values, averaging (4.128).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock slightly worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of vaccines and other pharmaceutical products
A.I.dvisor tells us that GSK and SNY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GSK and SNY's prices will move in lockstep.
|SNY - GSK|
|NVS - GSK|
|GILD - GSK|
|PFE - GSK|
|MRK - GSK|